Noteworthy, clinical studies have shown that circadian-timed quick-release bromocriptine treatment reduces significantly the risk of major adverse cardiovascular events in type 2 diabetes mellitus, non-hyperprolactinemic patients (109, 169).Among other effects (e.g., improving insulin sensitivity), a potential sympatholytic mechanism has been proposed (170). This evidence concerns the gene INS and type 2 diabetes mellitus.